Glimepiride News
AHA: Actos (pioglitazone) May Slow Progression of Atherosclerosis
In a head-to-head trial with the sulfonylurea Amaryl (glimepiride), Actos (pioglitazone), a thiazolidinedione, appeared to slow the progression of a marker for atherosclerosis in patients with type 2 diabetes, researchers...
Diabetes Drug May Reduce Cardiovascular Risks
A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of...
Data Demonstrate Benefits of Initial Use of Rosiglitazone Maleate and Glimepiride Combination Tablet in People With Type 2 Diabetes
New research presented today at the 66th Annual Scientific Sessions of the American Diabetes Association (ADA) show the benefits of the initial use of Avandaryl in helping people with type 2 diabetes achieve blood sugar targets...
Visceral Adiposity, TG-Rich cholesterol Predict atherosclerosis in T2D Patients
The Chicago study compares the effects of pioglitazone versus Glimepiride on measures of atherosclerotic disease of the carotid artery (carotid intima-media thickness and electron beam tomography) and biochemical indices of...
Insulin initiation with once-daily premix insulin analogue
Researchers from the University of Iowa in Iowa City, USA, compared the efficacy of adding once-daily premixed insulin analogue in patients with type 2 diabetes in poor glycaemic control.
Displaying results 6 to 10 out of 15